HUTCHMED (China) Limited Share Price & Technical Analysis
HCM · $11.52 (+1.05%)
Healthcare / Drug Manufacturers - Specialty & Generic
$11.52
+1.05%
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast ca…
Price chart
Seasonality
Jun has 3 positive and 2 negative years (last 5 years shown)
-1% return in Jun, 1% avg return in past 3 year Jun month.
-9% return in 2026, -1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 13% | -2% | 7% | -11% | -16% | -1% | – | – | – | – | – | – | -9% |
| 25 | -11% | 24% | -7% | -8% | -7% | 11% | 15% | -14% | 5% | -8% | -3% | -8% | -10% |
| 24 | -29% | 18% | 10% | 10% | 1% | -8% | 12% | -7% | 13% | -9% | -9% | -17% | -15% |
| 23 | 15% | -12% | -25% | 18% | -21% | 1% | 19% | 1% | 11% | 15% | -2% | 0% | 21% |
| 22 | -22% | 0% | -31% | -21% | -8% | 21% | 3% | -1% | -30% | -1% | 30% | 10% | -49% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Oversold
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.99B
P/E ratio
4.36
52W high
$19.50
52W low
$11.10
Volume
1,39,022
Beta
0.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is HUTCHMED (China) Limited share price today?
- HUTCHMED (China) Limited (HCM) last traded around $11.52 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HCM have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HCM. Download the app for real-time alerts.
- How can I analyze HUTCHMED (China) Limited stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.